title: The incidence of reflux oesophagitis after cure of Helicobacter pylori in a Japanese population.
abstract: OBJECTIVE
  To investigate the incidence of reflux oesophagitis after antibacterial therapy for Helicobacter pylori infection in our patient population.
  
  
  METHODS
  Subjects were 451 H. pylori-infected patients (primary symptom: peptic ulcer disease in 347, nonulcer dyspepsia in 100, and reflux oesophagitis in four): 11 of these patients had reflux oesophagitis on study entry. H. pylori infection was treated by a proton pump inhibitor/amoxycillin-clarithromycin regimen for either 7 or 14 days. Each patient was examined by endoscopy before treatment and more than 6 months after treatment to compare oesophageal findings. In addition, 227 patients were interviewed regarding reflux symptoms, using symptom questionnaires, before and more than 6 months after treatment.
  
  
  RESULTS
  Among 440 patients who did not have reflux oesophagitis prior to antibacterial treatment (340 peptic ulcer patients and 100 nonulcer dyspepsia patients), 23 patients whose infection was eradicated developed reflux oesophagitis (5.4%). The 11 patients who had reflux oesophagitis prior to treatment were all successfully cured of infection. Six of these patients showed no change in their oesophagitis, while the condition improved in three and worsened in two. Symptom scores improved in 34 of the 36 patients who reported reflux symptoms. Among 19 patients who showed persistent infection, only one developed reflux oesophagitis (5.2%), while none complained of newly developed symptoms following treatment.
  
  
  CONCLUSIONS
  Development of reflux oesophagitis after treatment of H. pylori infection was observed in a Japanese population. However, the incidence of this condition was comparable between those with persistent H. pylori infection and those in whom the infection was eradicated.
authors.affiliation: Department of Gastroenterology, Juntendo University School of Medicine, Tokyo, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Murai
authors.forename: H
authors.initials: H
authors.lastname: Miwa
authors.forename: R
authors.initials: R
authors.lastname: Ohkura
authors.forename: R
authors.initials: R
authors.lastname: Iwazaki
authors.forename: A
authors.initials: A
authors.lastname: Nagahara
authors.forename: K
authors.initials: K
authors.lastname: Sato
authors.forename: T
authors.initials: T
authors.lastname: Yamada
authors.forename: K
authors.initials: K
authors.lastname: Ota
authors.forename: H
authors.initials: H
authors.lastname: Tanaka
authors.forename: M
authors.initials: M
authors.lastname: Kawabe
authors.forename: T
authors.initials: T
authors.lastname: Minowa
authors.forename: Y
authors.initials: Y
authors.lastname: Takei
authors.forename: A
authors.initials: A
authors.lastname: Miyazaki
authors.forename: N
authors.initials: N
authors.lastname: Sato
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D004942:Esophagitis, Peptic / Q000453:epidemiology* / Q000382:microbiology; D005260:Female; D016481:Helicobacter Infections / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D015994:Incidence; D007564:Japan / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D010437:Peptic Ulcer / Q000150:complications; D012189:Retrospective Studies
chemical_list: D000900:Anti-Bacterial Agents